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ABSTRACT 
We synthesized substituted benzaldehyde derived α-hydroxyphosphonates (αOHP), α-
hydroxyphosphonic acids (αOHPA) and α-phosphinoyloxyphosphonates (αOPP) and characterized 
their cytotoxicity against a panel of cancer cell lines. A library containing 56 analogues was screened 
against Mes-Sa parental and Mes-Sa/Dx5 multidrug resistant uterine sarcoma cell lines, using a 
fluorescence-based cytotoxicity assay. The cytotoxicity screening revealed that dibenzyl-αOHPs and 
dimethyl-α-diphenyl-OPPs were the most active clusters, which encouraged us to synthesize further 
dibenzyl-α-diphenyl-OPP derivatives that elicited pronounced cell killing. Further structure-activity 
relationships showed the relevance of hydrophobicity and the position of substituents on the main 
benzene ring as determinants of toxicity. The most active analogs proved to be equally, or even more 
toxic to the multidrug resistant (MDR) cell line Mes-Sa/Dx5, suggesting these compounds may 
overcome P-glycoprotein mediated multidrug resistance by evading the drug transporter. 
Footnotes 
Electronic supplementary information (ESI) available: δP and MS value of the analogues; primary growth 
inhibition values; reaction time and yield of products. 
1. Introduction 
Organophosphonate derivatives, such as α-hydroxyphosphonates (αOHP), α-hydroxyphosphonic acids 
(αOHPA) and α-phosphinoyloxyphosphonates (αOPP) are a class of compounds of chemical and 
biological relevance. In synthetic chemistry, αOHPs are used in the synthesis of α-aminophosphonates, 
α-alkoxy-, or α-acyloxyphosphonates, ketophosphonates or α-halophosphonates.1 In addition, several 
αOHPs, αOHPAs and αOPPs were found to be biologically active. For example, organic phosphonates 
were reported to possess moderate viral cysteine protease inhibitory,2 antimicrobial or antifungal 
activities.3-5 The αOPP SR-202 inhibits human peroxisome proliferator-activated receptor-γ (PPARγ), 
influencing insulin sensitivity and glucose consumption of cells.6, 7 Studies have shown that organic 
phosphonates may influence cancer progression through the inhibition of farnesyl protein transferase 
(FPT)8, which has emerged as a novel target for anti-cancer agents due to its role in the 
posttranslational modification of the Ras oncogene,9 or purine nucleoside phosphorylase (PNP), as PNP 
inhibitors are potentially applicable in the management of certain hematologic malignancies.10, 11 
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However, to date, the direct anticancer activity of αOHP, αOHPA and αOPP analogues have not been 
systematically tested.12 
In a recent study we identified cytotoxic αOHP analogues using the uterine sarcoma Mes-Sa cells.13  
Here our aim was to synthesize and characterize the cytotoxic profile of a diverse compound set, and 
to draw basic structure activity relationships against a panel of cell lines, including Mes-Sa/Dx5, the 
multidrug resistant (MDR) derivative of the Mes-Sa cell line. 
2. Results and discussion 
2.1. Synthesis and compilation of the chemical library 
The derivatives were synthesized through the Pudovik reaction and subsequent modifications. 
Considering green chemical aspects, the reactions were performed either without solvent or in a 
minimal quantity of acetone, and the pure products were crystallized after reflux and adding a small 
amount of n-pentane14 (Scheme 1, Scheme 2 and Scheme 3).  
 R1 R2 Y1 Y2 Y3 Yield (%) 
1a H Me  -  -  - 95 
1b     Cl  -  - 93 
1c      - Cl  - 93 
1d      -  - Cl 90 
1e     NO2  -  - 95 
1f      -  - NO2 95 
1g      - Me  - 92 
1h      -  - Me 89 
1i     O-Me  -  - 68 
1j      - O-Me  - 98 
1l      -  - F 96 
2a   Et  -  -  - 78 
2b     Cl  -  - 80 
2c      - Cl  - 98 
2d      -  - Cl 79 
2e     NO2  -  - 89 
2f      -  - NO2 88 
3a  Bn  -  -  - 95 
3b     Cl  -  - 93 
3c      - Cl  - 88 
3d      -  - Cl 95 
3e     NO2  - -  91 
3f      -  - NO2 99 
3g      - Me  - 88 
3h      -  - Me 94 
3i     O-Me  -  - 96 
4a Me Me  -  -  - 48 
4f      -  - NO2 82 
4k     F  -  - 56 
4l      -  - F 38 
4m      - Br  - 89 
4n      -  - Br 72 
5f   Et  -  - NO2 65 
 
Scheme 1. General scheme of the synthesis and the synthesized series of αOHPs (1, 2, 3, 4 and 5). Dash 





 Y1 Y2 Y3 Yield (%) 
6a  -  -  - 80 
6b Cl  -  - 85 
6c  - Cl  - 76 
6d  -  - Cl 88 
6g  - Me  - 77 
6h  -  - Me 90 
6i O-Me  -  - 72 
6o  -  - NH2 50 
 
Scheme 2. General scheme of the synthesis and the synthesized αOHPAs (6). Dash signs in the table 
under Y1 – Y3 refer to hydrogen; Bn: benzyl. 
 
 
R2 Y1 Y2 Y3 Y4 Y5 
Yield 
(%) 
7a Me  -  -  - 
Ph Ph 
57 
7d    -  - Cl 61 
7e   NO2  -  - 79 
7f    -  - NO2 70 
7h    -  - Me 49 
8a    -  -  - 
 
59 
8d    -  - Cl 54 
8f    -  - NO2 72 
8h    -  - Me 46 
9a    -  -  - 
 
59 
9d    -  - Cl 51 
9f    -  - NO2 80 
9h    -  - Me 50 
10a Bn  -  -  - 
Ph Ph 
81 
10c    - Cl  - 57 
 
Scheme 3. General scheme of the synthesis and the synthesized series of αOPPs (7, 8, 9 and 10). Dash 
signs in the table under Y1 – Y3 refer to hydrogen; Bn: benzyl; Ph: phenyl. 
 
2.2. Primary screening of the phosphonate library 
A library containing 56 derivatives of αOHPs, αOHPAs and αOPPs was screened against the Mes-Sa 
parental and Mes-Sa/Dx5 multidrug resistant uterine sarcoma cell lines, both engineered previously to 
express the mCherry fluorescent protein (Mes-Sa mCh and Mes-Sa/Dx5 mCh).15 Primary cytotoxicity 





based on the fluorescence intensity of mCherry. At 20 μM, none of the analogues were effective, while 
at 200 μM, 11 entities (3a-c, 3e-i, 7a, 7d-e, 7h) were toxic to both Mes-Sa mCh and Mes-Sa/Dx5 mCh, 
and 3 additional compounds (3d, 4f, 7f) were selectively toxic to Mes-Sa/Dx5 mCh (Table S2). 
2.3. Confirmation of dose-dependent cytotoxicity 
Based on their primary cytotoxic effect, dibenzyl-αOHPs (3a-i) and dimethyl-α-diphenyl-OPPs (7a, 7d-
f, 7h) were chosen for further investigations. As these two classes of analogues can be chemically 
‘combined’, we designed and synthesized dibenzyl-α-diphenyl-OPP compounds (10a, 10c) to see if we 
can produce analogues with increased cytotoxic potency. 
We acquired dose-response curves and determined cytotoxicity as IC50 values against Mes-Sa mCh and 
Mes-Sa/Dx5 mCh cells. Against Mes-Sa mCh, 3a-i exerted moderate toxicity (IC50 values ranging from 
83 to 105 μM), except for the para-chloro (3d) and para-methyl (3h) substituted entities, which were 
remarkably less toxic with IC50 values exceeding 250 μM. Interestingly, multidrug resistant Mes-Sa/Dx5 
mCh cells were more sensitive to these compounds (3a-i), with IC50 values in the range of 34 - 78 μM, 
and 126 μM for 3h. Compounds 7a, 7d-f and 7h were also only moderately toxic against the Mes-Sa 
mCh cell line (IC50 values between 98 - 270 μM) and against Mes-Sa/Dx5 mCh (35 - 221 μM). 
Remarkably, the newly synthesized analogues 10a and 10c showed increased toxicity with IC50 values 
around 10 μM against both Mes-Sa mCh and Mes-Sa/Dx5 mCh cells (Fig. 1A). 
Since most compounds exerted significantly greater toxicity against the Mes-Sa/Dx5 mCh cell line than 
against Mes-Sa mCh, and since Mes-Sa/Dx5 mCh cells are multidrug resistant due to the 
overexpression of P-glycoprotein (P-gp), we checked if the paradoxical selective toxicity of the 
analogues were linked to the function of P-gp, as in the case of the so-called MDR-selective 
compounds.15-18 However, the presence of the P-gp inhibitor tariquidar did not influence the selective 
toxicity of the compounds (Fig. 1B), suggesting that the observed collateral sensitivity was linked to 
other, cell line-specific factor(s) acquired by Mes-Sa/Dx5 cells during doxorubicin selection. On the 
other hand, no compounds were found to be effluxed by the transporter, thus the tested compounds 
can overcome this clinically important form of multidrug resistance. 19-21 
To test the broader potency of the analogues, we selected 3 further cell lines originating from tumor 
types known to show poor response in the clinics. We investigated the cytotoxicity against HT-29 
rectosigmoid adenocarcinoma and HOP-62 lung adenocarcinoma cell lines, and against the MALME-
3M metastatic melanoma cell line transfected with eGFP to allow detection of cell survival in a 
fluorescent protein-based assay. 22 In addition to 9 analogues of dibenzyl-α-OHPs (3a-i) we tested 7a, 
10a and 10c. We found that 10a and 10c were much more toxic to all 3 cell lines, than the other 
analogues (Table 1). 
As previously was suggested, organic phosphonates may have an effect on the function of RAS proteins 
by inhibiting FTP which farnesylates RAS.8 To test whether the compounds we synthesized are showing 
mutant KRAS-specific toxicity, we tested 4 cytotoxic compounds (3c, 7a, 10a and 10c) on a parental 
(H838) and on a mutant KRAS expressing (H838-G12D) lung adenocarcinoma cell line. However, no 
specific hypersensitivity or resistance to the tested molecules was observed against the H838-G12D 
cells (Table 1). These results could be explained by several ways: (1) the used αOHPs do not inhibit FTP, 
(2) growth and survival of H838 cells do not rely on KRAS activity or (3) FTP inhibition is not sufficient, 
because geranylgeranylation might activate KRAS and suppresses the effect of FTP inhibition.23 
Nevertheless, the selected 4 compounds showed toxicity against both cell lines suggesting a more 




Table 1. IC50 values of compounds 3a-i, 7a, 10a and 10c against HT-29 and HOP-62 cell lines, measured 
by PrestoBlue viability reagent, against Malme-3M eGFP cell line measured by the fluorescent protein-
based assay, and against H838 and H838-G12D cell lines measured by MTT assay. Numbers represent 
IC50 values and standard deviations (sd) calculated from the individual pIC50 values. 
 
  HT-29  HOP-62  
MALME-3M 
eGFP  H838  H838-G12D 




+ 74.1  236.8 
+ 25.7  115.3 
+ 37.1         












+ 8.8  112.8 
+ 3.7  82.0 
+ 11.6         









+ 7.3  89.5 
+ 1.9  79.4 
+ 3.7  116.6 
+ 3.9  109.5 
+ 5.2 













  173.4 
+ 55.4  151.5 










+ 16.7  97.8 
+ 18.5  76.5 
+ 8.4         









+ 16.5  104.9 
+ 5.3  89.5 
+ 10.9         









+ 10.3  95.3 
+ 7.5  84.4 
+ 12.7         










  >>500 
 
  215.4 










+ 9.6  110.9 
+ 11.8  88.3 
+ 3.7         
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7a  337.1 
+ 40.4  301.8 
+ 27.7  214.2 
+ 26.4  226.0 
+ 0.5  180.1 
+ 1.3 




+ 1.1  26.5 
+ 2.3  30.7 
+ 2.7  18.6 
+ 0.6  14.4 
+ 0.1 












+ 4.4  
15.1 
+ 5.3  
13.4 
+ 0.1  
14.4 
+ 0.3  
13.7 
+ 0.6 
  - 3.7   - 
3.9 
  - 
0.1 
  - 
0.3 




2.4. Toxicity against the human non-cancerous cell line HFF 
Cancer specific toxicity of representatives of our compound library (3c, 7a, 10a and 10c) was probed 
against the human foreskin fibroblast (HFF) cell line. Based on the IC50 values (Table 2), we observed 
selectivity over tumor cells (note that HOP-62 and HT-29 cell lines were probed with the same viability 
reagent as HFF). The more pronounced vulnerability of cancer cells was not obvious, since in a study 
reporting the cytotoxicity of ß-formyl-α-hydroxyphosphonate derivatives, 2 out of 3 test compounds 




Table 2. IC50 values of compounds 3c, 7a, 10a and 10c against HFF, measured by PrestoBlue viability 
reagent. Numbers represent IC50 values and standard deviations (sd) calculated from the individual 
pIC50 values. 
  HFF 
   IC50 ± sd 
3c  242.2 
+ 23.4 
 - 25.9 
7a  >>400   
   
10a  61.2 
+ 1.6 
 - 1.6 
10c  32.8 
+ 3.4 
  - 3.7 
 
2.5. Investigation of cell death 
As apoptotic cells can be quickly cleared by macrophages, while cell debris derived from necrosis can 
cause inappropriate inflammation, apoptosis is the preferred cell death mechanism, when drug 
candidates are tested.25, 26 To elucidate the mechanism of cytotoxicity of our analogues, we performed 
Annexin binding assays27. As shown in Fig. 2, treatment with either 3c or 10c induced apoptosis, and 
the proportion of late apoptotic/necrotic cells was increased remarkably after 48 h treatment. 
 
2.6. Relationship of primary toxicity and lipophilicity 
Growth inhibition at 200 μM (Table S2) shows correlation with the lipophilicity of the compounds (Fig. 
3). With the exception of 4f and 5f (which had an approx. 50% inhibition against Mes-Sa/Dx5 mCh), 
compounds below a logP (partition coefficient) of 3 were not toxic. With a logP between 4-6, 
compounds were likely to be active. Furthermore, the most toxic analogues 10a and 10c have a logP 
of 9.3 and 8.8, respectively. Based on drug-like filters such as Lipinksi’s rule of 5 and the Ghose filter, 
logP of drugs are preferred to be under 5 or between -0.4 and +5.6, respectively.28, 29 One possibility 
of further drug development of 10a and 10c is to increase their hydrophilicity by introducing certain 
substituents, or/and design formulations that ensure their adequate bioavailability. As an example, 
Navitoclax, an anticancer Bcl-2 inhibitor that has a logP of 8.06 can be administered orally in a lipid 
solution.30 Similarly, formulations of venetoclax31 (logP: 6.76) and bexarothene32 (logP: 6.94), which 
are also in use for cancer, play a key role. 
 
2.7. Toxicity patterns 
In general, αOHPAs (6), such as dimethyl- and diethyl-αOHPs (1, 2, 4, 5) were not toxic, although an 
extra α-methyl-moiety improved toxicity (based on the activity of 4f and 5f against Mes-Sa/Dx5 mCh). 
However, when dibenzyl-αOHPs were investigated (3), toxicity increased remarkably. This increase in 
activity was observed also when dimethyl- and dibenzyl- αOPPs (7 and 10) were compared. We found 
relevant features linked to the position of the substituents on the main benzene ring. When the 
substituent was chlorine, the toxicity increased in the direction of para < ortho ≤ meta positions 
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throughout the cell panel. In the case of the NO2 group, the ortho-position was also beneficial as 
compared to the para-position, especially in the case of Mes-Sa/Dx5 mCh. Moreover, the meta-
position was much more beneficial than the para-position when methyl substitutions were present. 
This pattern indicates that substituents in the meta-position were preferred among 3a-i (Table 3). Our 
results provide the first detailed insights of the structure-anticancer activity relationship of the said 
organophosphonates, as earlier studies on salicylaldehide derived αOHPs12 or on ß-formyl-αOHPs24 
identified only a few compounds with cytotoxic potential, without relevant SAR observations. 
Table 3. Relative toxicity of 3a-i. IC50 values were normalized to the IC50 of the unsubstituted benzene 
ring containing compound (3a). Substituents on the benzene ring: o (ortho) refers to Y1; m (meta) 
refers to Y2 and p (para) to Y3 (Scheme 1). Mean rel. IC50 is the average of the individual relative IC50 
values. 
  
substituent  Mes-Sa  
Mes-
Sa/Dx5 
 Malme-3M  HT-29  HOP-62  Mean rel. 
   (Y1-Y2-Y3) 
 mCh  mCh  eGFP        IC50 
3a  H  1  1  1  1  1  1 
3b  o-Cl  0.88  0.78  0.69  0.37  0.47  0.64 
3c  m-Cl  0.89  0.54  0.66  0.37  0.38  0.57 
3d  p-Cl  2.86  1.02  1.31  1.69  0.76  1.53 
3e  o-NO2  0.90  0.45  0.64  0.40  0.42  0.56 
3f  p-NO2  1.02  0.87  0.75  0.44  0.44  0.70 
3g  m-Me  1.11  0.99  0.71  0.40  0.40  0.72 
3h  p-Me  2.87  1.70  1.88  1.69  2.10  2.05 
3i   o-O-Me   0.89   0.97   0.74   0.52   0.47   0.72 
 
3. Conclusions 
By synthesizing and testing a library of αOHPs, αOHPAs and αOPPs, we identified potent anticancer 
agents inducing apoptosis in several cell lines of different origin. The relation between growth 
inhibition and hydrophobicity (logP) was revealed and quantified, which can be exploited as an in silico 
pre-screening step in future studies. Based on the IC50 values, we observed the increased toxicity of 
dibenzyl-αOHPs (3) and dibenzyl-αOPPs (10) compared to the other analogues, and found that the 
most beneficial position for a substituent on the main benzene ring was the meta-position. These 
results are so far the most detailed SAR observations pertaining to αOHPs, αOHPAs and αOPPs. We 
also noticed the collateral sensitivity of the multidrug resistant Mes-Sa/Dx5 mCh cell line against most 
of the tested analogues. Although this hypersensitivity was independent from the function of P-
glycoprotein, the results show that the tested analogues can overcome multidrug resistance by 
evading the transporter. 
4. Experimental 
General procedure for the synthesis of α-hydroxyphosphonates 1, 2 and 3 
A mixture of 11.0 mmol of aromatic aldehyde (benzaldehyde: 1.2 g, 2-chlorobenzaldehyde: 1.5 g, 3-
chlorobenzaldehyde: 1.5 g, 4-chlorobenzaldehyde: 1.5 g, 2-nitrobenzaldehyde: 1.7 g, 4-
nitrobenzaldehyde: 1.7 g, 3-methylbenzaldehyde: 1.3 g, 4-methylbenzaldehyde: 1.3 g, 2-
methoxybenzaldehyde: 1.5 g, 3-methoxybenzaldehyde: 1.5 g, 4-fluorobenzaldehyde: 1.4 g ), 11.0 
mmol of dialkyl phosphite (dimethyl phosphite: 1.1 mL, diethyl phosphite: 1.4 mL and dibenzyl 
phosphite: 2.4 mL) and 1.10 mmol (150 μl) of triethylamine was stirred in 1 mL of acetone at reflux. 
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After 5–390 min, 6 mL of pentane was added to the reaction mixture. On cooling, the product 
crystallized from the reaction mixture. Filtration afforded products 1, 2 and 3 in a purity of > 99%. 
General procedure for the synthesis of α-hydroxyphosphonates 4 and 5 
A mixture of 11.0 mmol of aromatic ketone (acetophenone: 1.3 g, 2-fluoroacetophenone: 1.5 g, 4-
fluoroacetophenone: 1.5 g, 3-bromoacetophenone: 2.2 g, 4-bromoacetophenone: 2.2 g, 4-
nitroacetophenone: 1.8 g), 11.0 mmol of dialkyl phosphite (dimethyl phosphite: 1.1 mL or diethyl 
phosphite: 1.4 mL) and 11.0 mmol (1.5 mL) of triethylamine was stirred at 25 °C for 2–7 h.  Completion 
of the reaction was indicated by the crystallization of the product from the reaction mixture. The 
reaction mixture was cooled to 5 °C. After the crystallization was complete, the white crystals were 
filtered off and were washed with 2 mL of hexane to afford 4a, 4f, 4k, 4l, 4m, 4n and 5f in yields of 38–
89%. 
General procedure for the synthesis of α-hydroxyphosphonic acids 6 
4.1 mmol of α-hydroxyphosphonate (3a: 1.5 g, 3b: 1.7 g, 3c: 1.7 g, 3d: 1.7 g, 3f: 1.7 g, 3g: 1.6 g, 3h: 1.6 
g, 3i: 1.6 g) was hydrogenated in the presence of 10% Pd/C (Selcat Q) (0.08–0.09 g, the 
catalyst/substrate ratio was 0.05 g/g) in 30 mL of methanol in a 80-mL stainless steel autoclave 
equipped with a magnetic stirrer (stirring speed = 1100 rpm). The hydrogenations took place at 10 bar 
and 25 °C in 5–150 minutes. Then, the catalyst was filtered off, and activated carbon (0.15–0.17 g) was 
added to the solution. After 1 h of stirring, the absorbent was filtered off, and the organic solvent was 
evaporated. 5 mL of CH2Cl2 was added to the crude product and stirred for 15 min at reflux. After 
filtration, α-hydroxyphosphonic acids were obtained in yields of 50–90%. 
General procedure for the synthesis of α-phosphinoyloxyphosphonates 7, 8, 9, and 10 
A mixture of 1.0 mmol of -hydroxyphosphonate (1a: 0.22 g, 1d: 0.25 g, 1e: 0.26 g, 1f: 0.26 g , 1h: 0.23 
g, 3a: 0.37 g, 3c: 0.40 g), 5 mL of toluene, 1.2 mmol (0.17 mL) of triethylamine and 1.1 mmol of 
phosphinic chloride (diphenylphosphinic chloride: 0.21 mL, 1-chloro-3-methyl-3-phospholene-1-oxide: 
0.17 g or 1-chloro-3,4-dimethyl-3-phospholene-1-oxide: 0.18 g) was stirred at 25 °C for 24-48 h under 
N2 atmosphere. The precipitated triethylamine hydrochloride salt was filtered off, and the volatile 
compounds were removed under vacuum. The purification of the crude product with column 
chromatography on silica gel, using acetone:dichloromethane = 2:1 as the eluent afforded the 
corresponding α-phospinoyloxyphosphonates (7, 8, 9 and 10). 
The identity of the analogues that were known from the literature were validated by the δP and MS 
values (Table S1). 
7e. Yield: 79% 31P NMR (CDCl3) δ 17.0 (d, 3J = 26.9, P(O)(OCH3)2), 34.6 (d, 3J = 27.0, P(O)Ph2); 13C NMR 
(CDCl3) δ 53.8 (d, 2J = 6.7, OCH3), 54.3 (d, 2J = 7.0, OCH3), 66.1 (dd, 1J = 170.5, 2J = 5.9, PCH), 124.9 (d, 4J 
= 2.1, C3), 128.4 (d, 3J = 13.5, C3’), 128.6 (d, 3J = 13.4, C3’), 129.2 (d, 5J = 2.7, C4), 133.4 (d, 4J = 2.8, C5), 
130.0 (d, 3J = 4.9, C6) overlapped by 130.0 (C1), 131.5 (d, 1J = 146.8, C1’), 131.6 (d, 2J = 10.5, C2’), 131.90 
(d, 1J = 130.1, C1’), 131.93 (d, 2J = 10.5, C2’), 132.5 (d, 4J = 2.9, C4’), 132.8 (d, 4J = 3.1, C4’), 147.0 (d, 3J = 
5.3, C2); 1H NMR (CDCl3) δ 3.62 (d, 3JP,H = 10.8, 3H, OCH3), 3.75 (d, 3JP,H = 10.8, 3H, OCH3), 6.80 (dd, 2,3JP,H 
= 11.1, 15.5, 1H, PCH), 7.31-7.74 (m, 10H, Ar), 7.88-8.03 (m, 4H, Ar). 
10a. Yield: 81% 31P NMR (CDCl3) δ 18.1 (d, 3J = 28.0, P(O)(OBn)2), 35.0 (d, 3J = 28.0, P(O)Ph2); 13C NMR 
(CDCl3) δ 68.5 (d, 2J = 6.9, CH2), 68.6 (d, 2J = 7.2, CH2), 72.2 (dd, 1J = 173.1, 2J = 7.1, PCH), 127.2 (d, 3J = 
6.0, C2), 127.8-128.6 (m, C4, C3’, C2”, C3”, C4”), 128.9 (d, 4J = 2.8, C3), 130.89 (d, 1J = 138.2, C1’), 130.97 (d, 
1J = 134.0, C1’), 131.7 (d, 2J = 10.5, C2’), 131.8 (d, 2J = 10.6, C2’), 132.1 (d, 4J = 3.0, C4’), 132.4 (d, 4J = 2.9, 
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C4’), 133.4 (t, 2J = 1.3, 3J = 1.3, C1), 135.8 (d, 3J = 6.0, C1”), 136.0 (d, 3J = 5.8, C1”); 1H NMR (CDCl3) δ 4.67-
5.10 (m, 4H, 2xCH2), 5.75 (dd, 2,3JP,H = 10.8, 13.1, 1H, PCH), 7.03-7.90 (m, 25H, Ar). 
10c. Yield: 57% 31P NMR (CDCl3) δ 17.6 (d, 3J = 28.0, P(O)(OBn)2), 35.5 (d, 3J = 28.2, P(O)Ph2); 13C NMR 
(CDCl3) δ 68.6 (d, 2J = 6,8, CH2), 68.8 (d, 2J = 7.3, CH2), 71.4 (dd, 1J = 173.2, 2J = 6.5, PCH), 126.5 (d, 3J = 
5.9, C6), 127.9-128.7 (m, C3’, C2”, C3”, C4”) overlapped by 128.4 (d, 3J = 6.1, C2) 129.0 (d, 5J = 2.7, C4), 129.5 
(d, 4J = 1.9, C5), 130.5 (d, 1J = 137.8, C1’), 130.7 (d, 1J = 134.5, C1’), 131.7 (d, 2J = 10.6, C2’), 131.8 (d, 2J = 
10.6, C2’), 132.3 (d, 4J = 3.0, C4’), 132.5 (d, 4J = 2.9, C4’), 134.1 (d, 4J = 2.3, C3), 135.4 (t, 2J = 1.4, 3J = 1.4, 
C1), 135.6 (d, 3J = 6.1, C1”), 135.8 (d, 3J = 5.5, C1”); 1H NMR (CDCl3) δ 4.76-5.05 (m, 4H, 2xCH2), 6.80 (dd, 
2,3JP,H = 10.3, 11.1, 1H, PCH), 7.07-7.89 (m, 24H, Ar). 
4.1. Cell lines and culture conditions 
To assess anticancer cytotoxicity, we used the HOP-62 lung adenocarcinoma, HT-29 rectosigmoid 
adenocarcinoma, Malme-3M melanoma and Mes-Sa and the multidrug resistant Mes-Sa/Dx5 uterine 
sarcoma cell lines, and in addition H838 and KRAS mutant H838-G12D lung adenocarcinoma cell lines. 
The uterine sarcoma lines and the human foreskin fibroblast (HFF) cells were obtained from ATCC, and 
were maintained in DMEM. H838 cells were from Horizon Discovery Group plc., while the other lines 
were purchased from the NCI DTP, and were cultivated in RPMI. Media were supplemented with 10 % 
FBS, 5 mmol/L glutamine, and 50 unit/mL penicillin and streptomycin (ThermoFisher), except for HFF, 
where we used a 20 % FBS containing medium. 
4.2. Fluorescent protein transfection. 
Mes-Sa and Mes-Sa/Dx5 cell lines were transfected with the fluorescent protein mCherry (mCh), and 
were already utilized in other studies.13, 15, 22 Establishment of the Malme-M3 eGFP was not described 
earlier, but it was created with the same method. Briefly, the Malme-M3 cell line was transduced with 
the fluorescent protein expressing lentiviral supernatants produced with pRRL-EF1-eGFP expression 
plasmid. After the transduction, cell lines were sorted by flow cytometry based on fluorescent 
intensity.  
4.3. Cytotoxicity assays 
Cells were seeded on 384 well plates 1 day prior to drug addition at a 2500 cells/well density in every 
scenario but the H838 lines, where 5000 cells were seeded on 96 well plates. In the primary screening, 
we assessed the cytotoxicity against Mes-Sa mCh and Mes-Sa/Dx5 mCh cell lines in 20 μM and in 
200 μM concentrations. Drug treatment took 96 h, then the fluorescent intensity of mCherry (ex/em: 
585/610 nm) was detected with an EnSpire multimode plate reader (Perkin Elmer). In the following 
step, cells were treated with the serial dilution of the drugs showing activity in the primary screen, and 
IC50 values were acquired after 144 h incubation time. Dose-response curves for 3a-i, 7a, 10a and 10c 
were obtained against 3 additional cell lines to prove general anticancer toxicity of the selected 
compounds. Cytotoxicity against Malme-M3 eGFP was assessed via the detection of eGFP fluorescence 
(ex/em: 485/510 nm) after 144 h incubation, while the IC50 values against HOP-62 and HT-29 were 
calculated from the detection of PrestoBlue viability reagent (Thermo Fisher) conversion at ex/em of 
555/585 nm wavelengths, 72 h post drug addition. Against compounds 3c, 7a, 10a and 10c, the viability 
of H838 lines were determined based on MTT assay, and based on PrestoBlue assay against HFF. 
4.4. Cell death assessment 
Annexin V/propidium iodide (PI) based apoptosis quantification was performed by using the Annexin 
V, FITC Apoptosis Detection Kit (Dojindo Molecular Technologies) according to the protocol provided 
by the manufacturer. Briefly, 1.5x105 HOP-62 cells were seeded on 12 well plates, treated with the 
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given drug at IC50 concentrations for 24 and 48 hours. Cells in the supernatant were collected and 
admixed with the cells that were detached with trypsin. Cells were stained for 15 minutes at room 
temperature in dark with 5 μl Annexin V and 5μl PI solution in a 10-fold diluted Annexin V binding 
buffer. Samples were analyzed by Attune NxT Flow Cytometer (Thermo Fisher Scientific). 
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Figure 1. (A) IC50 values of compounds 3, 7 and 10 against Mes-Sa mCh (red) and Mes-Sa/Dx5 mCh 
(blue) cell lines. Results of compounds 3 against Mes-Sa mCh were taken from our previous study.13 
(B) Cytotoxicity and selectivity ratio (SR = IC50 Mes-Sa mCh/IC50 Mes-Sa/Dx5 mCh) of compounds 3b-c, 
3e, 3h, 7a and 7d. IC50 values, standard deviations and significance (*, P < 0.05; **, P < 0.01) were 
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Figure 2. Induction of apoptosis of HOP-62 cells by 3c or 10c. The four quadrants indicate viable cells 
(Q1); only Annexin V positive cells (apoptosis, Q2); Annexin V and propidium-iodide positive cells (late 
apoptosis/necrosis, Q3); and only propidium-iodide positive cells (Q4). 
 
Figure 3. Growth inhibition of compounds at 200 μM after 96 h drug incubation as the function of logP. 
Compound groups from Scheme 1, 2 and 3 are presented with different colors, 1: light grey, 2: yellow; 
3: purple; 4: green; 5: black; 6: orange; 7: brown; 8: dark grey; 9: blue; 10: red. logP values were 
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